Kiyatec Inc.

KIYATEC is a biotechnology startup founded in 2005 that utilizes the patient’s own living tumor cells to create functional 3D models for testing various cancer therapies. The company's 3DKUBE technology platform integrates perfusion flow, supports all scaffold materials, enables in situ imaging, and replicates complex human biology through segregated cell co-culture. Notably, it is a single-use disposable system. With its 3DKUBE cell-based assays, KIYATEC aims to provide more accurate in vitro predictions of complex biochemical reactions in humans. This focus on evaluating drug toxicity and efficacy before they reach human clinical trials holds great potential for revolutionizing the field of cancer treatment. In May 18, 2023, the company secured a Venture Round investment from the Brain Tumor Investment Fund. This latest investment attests to the confidence of investors in KIYATEC and its innovative approach to cancer therapy.